XML 60 R29.htm IDEA: XBRL DOCUMENT v3.3.1.900
Organization and Significant Accounting Policies, Revenue Recognition (Details)
1 Months Ended 3 Months Ended 12 Months Ended
Jun. 30, 2015
USD ($)
Sep. 30, 2013
USD ($)
Dec. 31, 2012
USD ($)
Target
Jun. 30, 2012
USD ($)
Jan. 31, 2012
USD ($)
Jun. 30, 2015
USD ($)
Dec. 31, 2015
USD ($)
AccountingUnit
Agreement
Category
Stage
Dec. 31, 2014
USD ($)
Dec. 31, 2013
USD ($)
Revenue Recognition [Abstract]                  
Licensing and royalty revenue             $ 2,343,000 $ 11,647,000 $ 3,091,000
Collaborations and Licensing Agreements [Member]                  
Revenue Recognition [Abstract]                  
Number of categories of milestone events | Category             3    
Number of stages of life-cycle of drugs | Stage             3    
Collaborations and Licensing Agreements [Member] | Development Milestones - New Development Candidate [Member] | Minimum [Member]                  
Revenue Recognition [Abstract]                  
Completion period             12 months    
Collaborations and Licensing Agreements [Member] | Development Milestones - New Development Candidate [Member] | Maximum [Member]                  
Revenue Recognition [Abstract]                  
Completion period             18 months    
Collaborations and Licensing Agreements [Member] | Development Milestones - Phase 1 [Member] | Minimum [Member]                  
Revenue Recognition [Abstract]                  
Completion period             1 year    
Collaborations and Licensing Agreements [Member] | Development Milestones - Phase 1 [Member] | Maximum [Member]                  
Revenue Recognition [Abstract]                  
Completion period             2 years    
Collaborations and Licensing Agreements [Member] | Development Milestones - Phase 2 [Member] | Minimum [Member]                  
Revenue Recognition [Abstract]                  
Completion period             1 year    
Collaborations and Licensing Agreements [Member] | Development Milestones - Phase 2 [Member] | Maximum [Member]                  
Revenue Recognition [Abstract]                  
Completion period             3 years    
Collaborations and Licensing Agreements [Member] | Development Milestones - Phase 3 [Member] | Minimum [Member]                  
Revenue Recognition [Abstract]                  
Completion period             2 years    
Collaborations and Licensing Agreements [Member] | Development Milestones - Phase 3 [Member] | Maximum [Member]                  
Revenue Recognition [Abstract]                  
Completion period             4 years    
Collaborations and Licensing Agreements [Member] | Regulatory Milestones [Member] | Minimum [Member]                  
Revenue Recognition [Abstract]                  
Time to prepare and submit regulatory filings             6 months    
Time to obtain approval             1 year    
Collaborations and Licensing Agreements [Member] | Regulatory Milestones [Member] | Maximum [Member]                  
Revenue Recognition [Abstract]                  
Time to prepare and submit regulatory filings             12 months    
Time to obtain approval             2 years    
Collaborations and Licensing Agreements [Member] | Commercialization Milestones [Member]                  
Revenue Recognition [Abstract]                  
Example of sales threshold as milestone event             $ 1,000,000,000    
Bayer [Member] | Agreement Entered into in May 2015 [Member]                  
Revenue Recognition [Abstract]                  
Upfront fee received           $ 100,000,000      
Number of units of accounting | AccountingUnit             3    
Bayer [Member] | Agreement Entered into in May 2015 [Member] | IONIS-FXI [Member]                  
Revenue Recognition [Abstract]                  
Upfront fee recognized           91,200,000      
Upfront fee recorded as deferred revenue $ 8,800,000         $ 4,300,000      
Assumed change in estimated selling price           10.00%      
Percentage by which earned revenue would change based on assumed change in estimated selling price           1.00%      
Amount by which earned revenue would change based on assumed change in estimated selling price           $ 900,000      
Bayer [Member] | Agreement Entered into in May 2015 [Member] | IONIS-FXI Active Pharmaceutical Ingredient [Member]                  
Revenue Recognition [Abstract]                  
Upfront fee recorded as deferred revenue           $ 4,500,000      
Biogen [Member] | Collaborations and Licensing Agreements [Member]                  
Revenue Recognition [Abstract]                  
Number of collaborative agreements | Agreement             4    
Biogen [Member] | Agreement Entered into in January 2012 [Member] | Nusinersen [Member]                  
Revenue Recognition [Abstract]                  
Upfront fee recorded as deferred revenue         $ 29,000,000        
Biogen [Member] | Agreement Entered into in June 2012 [Member] | IONIS-DMPK-2.5 [Member]                  
Revenue Recognition [Abstract]                  
Upfront fee recorded as deferred revenue       $ 12,000,000          
Biogen [Member] | Agreement Entered into in December 2012 [Member] | Neurology [Member]                  
Revenue Recognition [Abstract]                  
Upfront fee recorded as deferred revenue     $ 30,000,000            
Number of targets | Target     3            
Biogen [Member] | Agreement Entered into in September 2013 [Member] | Strategic Neurology [Member]                  
Revenue Recognition [Abstract]                  
Upfront fee recorded as deferred revenue   $ 100,000,000              
Term of collaboration agreement             6 years    
Alnylam [Member]                  
Revenue Recognition [Abstract]                  
Licensing and royalty revenue               $ 9,500,000